Novo Nordisk Advances Amycretin to Phase 3 Trials for Weight Management Treatment
Novo Nordisk A/S has advanced its investigational treatment, amycretin, into phase 3 trials for weight management. This follows findings published in The Lancet and presentations at the ADA 85th Scientific Sessions. The trials evaluated the safety and weight loss potential of amycretin, which combines GLP-1 and amylin receptor agonism. Results showed it was tolerable with a safety profile similar to other treatments. The phase 3 trials will further assess its therapeutic potential for weight management.
Novo Nordisk A/S has announced the advancement of its investigational treatment, amycretin, into phase 3 trials for weight management. This decision follows the publication of findings in The Lancet and presentations at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, US. The clinical trials evaluated the safety, tolerability, and weight loss potential of both subcutaneous and oral forms of amycretin in individuals with overweight or obesity. The results indicated that amycretin was tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists. Amycretin is noted as the first treatment to combine GLP-1 and amylin receptor agonism in a single molecule, offering complementary effects on appetite control. The phase 3 trials aim to further assess its potential as a therapeutic option for weight management. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novo Nordisk A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001103993-en) on June 20, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)